Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Registration Number
- NCT00967291
- Lead Sponsor
- IRCCS San Raffaele
- Brief Summary
RATIONALE: Drugs used in chemotherapy, such as mitomycin C and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving mitomycin C together with ifosfamide works in treating patients with metastatic pancreatic cancer.
- Detailed Description
OBJECTIVES:
* To assess the therapeutic activity of a mitomycin C and ifosfamide combination, in terms of progression-free survival rate at 6 months, in patients with metastatic stage IV adenocarcinoma of the pancreas.
OUTLINE: Patients receive mitomycin C IV on day 1 and ifosfamide IV on days 1-3. Courses repeat every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 21
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Progression-free survival at 6 months every 2 months during therapy; every 3 months thereafter CT scan
- Secondary Outcome Measures
Name Time Method Toxicity monthly outpatient visit
Progression-free survival every 2 months during therapy; every 3 months thereafter CT scan
Overall survival monthly outpatient visit or phone interview
Trial Locations
- Locations (1)
Istituto Scientifico H. San Raffaele
🇮🇹Milan, Italy